Work

Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-c105

Authors: Peter J. Houghton, John M. Maris, Stephen T. Keir, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Kathleen R. Whiteman, Malcolm Anders Smith

Institutions: Nationwide Children's Hospital, Children's Hospital of Philadelphia, Duke Medical Center, Children's Cancer Institute Australia, Montefiore Medical Center, Alfred I. duPont Hospital for Children, Texas Tech University, Texas Tech University Health Sciences Center, ImmunoGen (United States), National Cancer Institute

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1981052157

Cites:

Cited by: 2

Related to: 10